Neuralgias of the Head: Occipital Neuralgia

Il Choi1 and Sang Ryong Jeon2

1Department of Neurological Surgery, Dongtan Sacred Heart Hospital, University of Hallym University, Hwaseong, Korea; 2Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Received: 13 November 2015
Accepted: 20 January 2016

Address for Correspondence:
Sang Ryong Jeon, MD
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
E-mail: srjeon@amc.seoul.kr

INTRODUCTION

According to the definition of the International Headache Society (IHS), occipital neuralgia (ON), also known as C2 neuralgia, involves paroxysmal shooting or stabbing pain in the dermatomes of the greater or lesser occipital nerve (GON or nervus occipitalis major) and the lesser occipital nerve (LON or nervus occipitalis minor). From an origin in the suboccipital region, the pain spreads throughout the vertex, particularly the upper neck, back of the head, and behind the eyes. The pain may be accompanied by hypesthesia or dysesthesia in the affected areas. The most common trigger is compression of the GON or LON (1), with the GON more frequently involved (90%) than the LON (10%) (2).

ETIOLOGY AND PATHOPHYSIOLOGY

Neuralgia is pain in one or more nerves caused by compression and/or irritation of peripheral nerve structures. In ON, irritation of the GON and/or LON by chronically contracted muscles and spondylosis of the upper cervical spine is often implicated (4,5). In addition, compression from intra- or extra cranial vessels, giant cell arteritis, callus formations after vertebral fractures, schwannomas, and other masses are rare causes of ON. The etiologies are summarized in Table 1.

CLINICAL PRESENTATION

Patients with ON suffer from a shooting or stabbing pain in the neck that radiates over the cranium. The pain is characterized as persistent, paroxysmally aggravating, and of variable distribution; can be perceived in the retro-orbital area due to the convergence of the C2 dorsal root and the nucleus trigeminus pars caudalis (6). Due to connections with the VIII, IX, and X cranial nerves and the cervical sympathetic, vision impairment/ocular pain (67%), tinnitus (33%), dizziness (50%), nausea (50%), and congested nose (17%) can also be present (7). On physical ex-

Keywords: Occipital Neuralgia; Third Occipital Nerve; Greater Occipital Nerve; Lesser Occipital Nerve; Cervicogenic Headache
Table 1. Known possible causes of irritation: vascular, neurogenic, muscular, and osteogenic

| Category   | Causes of irritation                                                                 |
|------------|--------------------------------------------------------------------------------------|
| Vascular   | • Irritation of the C1/C2 nerve roots by an aberrant branch of the posterior inferior cerebellar artery (369)  
• Dural arterovenous fistula at the cervical level (70)  
• Bleeding from a bultocervical cavernomas (71)  
• Cervical intramedular cavernous hemangioma (72)  
• Giant cell arteritis (73-75)  
• Fenestrated vertebra artery pressing on C1/C2 nerve roots (76)  
• Aberrant course of the vertebra artery (77) |
| Neurogenic | • Schwannoma in the area of the craniocervical junction: schwannoma of occipital nerve (78,79)  
• C2 myelitis (80)  
• Multiple sclerosis (81) |
| Osteogenic | • C1/C2 arthrosis, atlantodental sclerosis (82)  
• Hypermobile C1 posterior arch (83)  
• C1/C2 arthrosis, atlantodental sclerosis (82)  
• Hypermobile C1 posterior arch (83)  
• Cervical osteochondroma (84)  
• Osteolytic lesion of the cranium (85)  
• Exuberant callus formation after C1/C2 fracture (86) |

...amination, tenderness along the course of the GON and LON can be observed. Sometimes hypoesthesia or dysesthesia can occur. The pain is located in the occipital area and may spread toward the vertex. Though usually unilateral, it may be bilateral.

**DIAGNOSTIC METHODS**

According to the International Classification of Headache Disorder (ICHD-II), ON belongs to the same family as cranial neuralgias, central and primary facial pain, and other headaches. The diagnostic criteria are as below:

A. Paroxysmal stabbing pain, with or without persistent aching between paroxysms, in the distribution of the greater, lesser, and/or third occipital nerve  
B. Tenderness over the affected nerve  
C. Pain is eased temporarily by local anesthetic block of the nerve

**Physical examination**

Along the course of the GON (over the occipital protuberance) and/or the LON (about 3 cm superomedially to the tip of the mastoid process), tenderness is detected by palpation (8). Tingling may be evoked by light pressure or percussion on the nerve (Tinel’s sign). When patients lie on a pillow and hyperextend or rotate their neck, pain can occur (“pillow sign”).

**Imaging studies**

Magnetic resonance imaging is the most important tool in the diagnosis of this disorder as it enables visualization of the surrounding cervical and occipital soft tissues. A simple X-ray is useful to rule out underlying pathologies, such as arthritis and cranio cervical instability. A CT scan of the cranio cervical junction can reveal neoplastic or degenerative osseous pathology. Sometimes there may be a discrepancy between the radiological findings and the symptoms (9).

**Diagnostic block**

The clinical presentation (i.e., tenderness over the occipital nerves) and a temporary improvement in the headache with a local anesthetic diagnostic block of the occipital nerve on the affected side confirm the diagnosis (1). Occipital nerve block, as well as an essential diagnostic tool, can also be a good treatment option for ON. Thus, the anatomy of the occipital nerve and the location of the exact target site are very important. Clinicians should keep in mind that occipital nerve block relief is not specific for ON and that false-positive results occur with migraine and cluster headaches (7,10).

**Anatomy of the occipital nerve**

The GON is the largest pure sensory nerve in our body. The GON is the medial branch of the dorsal ramus of the C2 spinal nerve. The GON initially courses in a downward, lateral direction, makes the bend along the inferior oblique and is covered by the splenius capitis, the longissimus, and the semispinalis muscles. On rare occasions, the nerve travels intramuscularly within the inferior oblique muscle. The GON then turns upward and pierces the semispinalis capitis. Finally, it turns superolaterally to emerge into the scalp by piercing the aponeurotic fibrous attachment of the trapezius muscle and sternocleidomastoid muscle (SCM) to the superior nuchal line. At this exit site, the occipital artery and GON are closely associated. The GON splits and innervates the occipital skin (medial branches) and the region behind the pinna (lateral branches) immediately below the superior nuchal line (11-14). The emergence point of the GON is at the semispinalis muscle at a point 3 cm below the occipital protuberance and 1.5 cm lateral to the midline (13,15). Anatomical variations of GON are occasionally found, particularly in the vertical axis (16,17). The C2 ramus could be compressed between the posterior arch of the C1 and the lamina of the C2, but the nerve is not especially vulnerable at this location (11).

The LON originates from the dorsal ramus of the C2 and, occasionally, the C3. It ascends toward the occiput along the posterior border of the SCM. Near the cranium, it perforates the deep fascia and runs upward over the occiput, where it innervates the skin and communicates medially with the GON (18). Although there is some variability in the anatomy, the nerve mostly emerges from the posterior border of the SCM superior to the exit of the great auricular nerve. This point is approximately 6-7 cm lateral from the midline and 4-6 cm caudal to a line connecting the lowest points of the external auditory canals (15).

1) The Cruveilhier plexus: the connection among the C1, C2, and C3 sensory branches (Fig. 1)

Hollinshead stated that “The upper parts of the back muscles in the cervical region are also supplied by direct twigs from the dorsal rami of the second and third cervical nerves, and by branches that arise from the so-called posterior cervical plexus, a
very simple series of loops between the first and second and the second and third dorsal rami, sometimes also with a loop to the fourth (19). Articular branches of the C2-3 facet joint arising from communicating branches between the third occipital nerve and C2 dorsal ramus have also been found (20).

Neural interconnections, such as the Cruveilhier plexus, can affect the therapeutic results of cervical muscular and facet de-nervation procedures. Therefore, the anatomical variations in the craniocervical region, such as the Cruveilhier plexus, may result in resistant pain after partially destructive surgical procedures for ON (21).

2) The innervations of the C1, 2, and 3 nerves

Although the C1 nerve is not thought to innervate a cutaneous tissue, it supplies some sensory innervations to deep somatic tissues in the suboccipital region, including the short muscles of the occipital triangle, through its dorsal ramus, and the SCM, trapezius, and atlanto-occipital joint, through its ventral ramus. In addition, the sinuvertebral nerve of C1 innervates the median atlantoaxial joint, dura mater, and vertebral artery, in conjunction with the sinuvertebral nerves of the C2 and C3. The dorsal ramus of the C2 innervates the splenius capitis and semispinalis capitis and finally becomes the GON. The ventral ramus of the C2 supplies articular branches to the lateral C1/2 joint as well as the prevertebral muscles, SCM, and trapezius. The dorsal ramus of the C3 has three significant branches, the lateral, deep medial, and superficial medial branches. The lateral branch supplies the splenius capitis, cervicis, and longissimus capitis; the deep medial branch innervates the semispinalis cervicis and multifidus; and the superficial medial branch innervates the semispinalis capitis. The superficial medial branch is also known as the third occipital nerve, and innervates the C2-C3 zygapophyseal joint as well as the skin in the suboccipital region (22). Cervicogenic headache, which involves pain referral from cervical structures, appears to be produced by convergent excitation that is evoked by stimulation of these nerves and that results in excitation of second-order neurons in the tri-
The injection points are variable. One of the points is located on a line that connects the middle of the ears, 3.18 cm from the midline. The other point is situated 3.8 cm lateral to the midline and one quarter of the distance along a line connecting the external occipital protuberance to the mastoid (or 2 cm lateral and 2 cm inferior to the external occipital protuberance). Some authors have described this point as being 1.5 cm lateral and 2 to 2.5 cm inferior to the external occipital protuberance. Great variability in the course of the GON is described in the literature (18,25,27).

**Fig. 3.** Landmarks for injection of the occipital nerves and electrical stimulation; Rogier Trompert Medical Art, modified with permission from Vandevelde et al. (9).

**Injection point (Fig. 3)**

There are two important disease categories that clinicians should keep in mind. First, tumors, infections, and congenital anomalies (e.g., Arnold-Chiari malformation) should be distinguished. It is crucial to diagnose these disorders. If they are missed by clinicians, a devastating situation may result. ON can be mistaken for migraine, cluster headache, tension headache, or hemicraniectomy continua (28). ON must be distinguished from referred pain from the atlantoaxial or upper zygapophyseal joints or from trigger points in neck muscle or their insertions (cervicogenic headache) (23,24,28). The critical differential point is that ON is neuralgia from the occipital nerve, whereas cervicogenic headache is nociceptive referred pain from cervical structures.

**TREATMENT OPTIONS**

Since ON was first described in 1821, numerous causes have been suggested and a variety of interventions have been used in its treatment (29). Currently, there is still no clear consensus on the management of ON. Medication, physical therapy, minimal intervention, and aggressive surgery are applied step-by-step. Evidence for the success of this approach is relatively weak. In addition, well-designed studies have rarely been reported. Treatment methods include medication, nerve blocks and, in refractory cases, neurosurgical procedures. Education, patient support, and reassurance are also important components of treatment. Management of neuropathic pain, which can develop following long-standing ON, should address both the pain itself and the psychological aspects associated with it.
Conservative management
Conservative treatment includes posture correction and reducing the neuralgic and muscle pain. Pharmacological treatment may include tricyclic antidepressants, serotonin reuptake inhibitors, anticonvulsants (e.g., carbamazepine, oxcarbamazepine, gabapentin, pregabalin), and opioids. Nonsteroidal anti-inflammatory drugs and paracetamol tend to have transient effects. The use of ergot derivatives is controversial. Infliximab has shown some benefit (9,30-32).

Interventional management
Local anesthetic agent injection with or without steroid
Local anesthetic agent injection with steroid may be used for therapeutic purposes. This method usually has a transient effect, but in some cases (15%-36%) the pain subsidence may be maintained for several months (2,7,33).

Botulinum toxin infiltrations
Several studies have shown an analgesic effect of Botulinum toxin A (BoNT-A) that outlasted the duration of its muscle relaxant effect (1,34). A few theories have been proposed to explain this analgesic effect of the toxin (35-38). For instance, BoNT-A’s inhibitory effects on sensory nerve mediators like substance-P (36), calcitonin gene-related peptide (37), and glutamate (38) may be involved in pain relief. Botulinum toxin may directly inhibit local neurogenic inflammation and indirectly inhibit central sensitization by significantly decreasing the activity of wide dynamic range neurons (38). Clinically, Botulinum toxin has been successfully used to treat several different types of headaches, including tension-type headaches (39), cervicogenic headaches (40), migraine (41), and chronic daily headaches (39). BoNT-A injection can relieve the sharp, shooting pain associated with ON, though not dull, aching pain, and improve quality of life for several months (42,43). The studies conducted with Botulinum toxin are listed in Table 2.

Pulsed radiofrequency treatment
Pulsed radiofrequency (PRF) treatment is known to reduce pain, primarily by the induction of a low-intensity electrical field around sensory nerves that results in depressed conduction and inhibition of long-term activation in the lightly myelinated A-delta fibers and the small unmyelinated C fibers (44). In animal studies, PRF-mediated pain relief is suggested to be due to modulation of the descending noradrenergic and serotonergic pathways (45).

To date, a few reports have been published concerning PRF treatment of ON (Table 2). All reports were observational cohort studies without controls. The treatment in these ON studies showed short-term to intermediate-term pain control and the parameters used were: 40-60 V voltage output; 2 Hz frequency; 20-ms pulses in a 1-second cycle, 120 seconds/cycle; 150-500 W impedance range; and 42°C plateau temperature. The authors advise that careful attention to selection criteria and treatment parameters may further improve treatment outcomes (46-49).

Table 2. Publications on the treatment of ON with Botulinum toxin injection, pulsed radiofrequency (PRF), and nerve neurolysis

| Study | Study design | Case No. | Follow-up duration | Outcome measure method | Results |
|-------|-------------|----------|--------------------|------------------------|---------|
| Taylor et al. (42) 2008 | Retrospective | 6 | 12 wk | VPAM | Sharp/shooting pain significantly improved; Dull aching pain not significantly improved |
| Kapural et al. (43) 2007 | Case series | 6 | 4 wk | VAS, PDI | VAS 8.5 → 1, PDI 56 → 17.5 |
| Voity et al. (87) 2006 | A case report | 1 | N/A | N/A | Improved temporarily |
| Huang et al. (48) 2012 | Retrospective, multicenter | 102 | At least 3 mon | ≥ 50% pain relief for at least 3 mon | 51% positive result |
| Vanelderen et al. (49) 2010 | Prospective | 19 | 1, 2, and 6 mon | VAS, Likert scale | 52.6% significant improvement at 6 mon |
| Choi et al. (47) 2012 | Retrospective | 10 | 6-10 mon | VAS, TPI | All patients improved |
| Ducic et al. (54) 2008 | Retrospective | 206 | Minimal, 12 mon | ≥ 50% pain relief | 80.5% positive result |
| Gille et al. (52) 2004 | Retrospective | 10 | Mean, 37 mon (33-43) | 1) VAS, 2) Consumption of analgesics, 3) Patient satisfaction | 1) 80/100 → 20/100, 2) Decrease in all, 3) Satisfaction in all |
| Magnússon et al. (5) 1996 | Retrospective | 18 | Mean, 28.7 mon (12-38) | ≥ 75%: excellent, 50%-74%: good, 25%-49%: fair, < 24%: poor | 88.9% better than fair |

ON, occipital neuralgia; No., number; VPAM, visual analog pain and medication use diary; VAS, visual analog scale; PDI, pain disability index; N/A, not available; PRF, pulsed radiofrequency; TPI, total pain index; NRS, numerical rating scale.
Surgery

Surgical treatment of ON can be considered when a patient does not respond adequately to medical therapies, such as repeated injections, or minimally invasive procedures, such as PRF treatment. Neurolysis of the occipital nerve (with or without sectioning of the inferior oblique muscle), C2 gangliotomies, C2 ganglionectomy, C2 to C3 rhizotomies, C2 to C3 root decompression, and neu reectomy were historically introduced for medically refractory patients (5, 50–57). However, the results were variable. Recently, there have been a few positive reports on peripheral nerve stimulation, a less invasive surgery, of the GON or LON. Of these approaches, both occipital neurolysis and occipital nerve stimulation (ONS) have been used commonly in the clinical field, recently. In selective cases, these methods have shown good outcomes, but a well-designed randomization study with a long-term observation is not yet available. Clinicians should bear in mind the risk that destructive procedures carry, which include the possibility of the development of painful neuroma or causalgia, conditions that may be even harder to control than the original complaint (58).

Neurolysis

Entrapment of the GON in its peripheral course is a significant pathology in ON. Five potential sources of entrapment of the GON are suggested: C2 nerve root (rare), inferior oblique muscle (rare), within the semispinalis capitis muscle, within the trapezius muscle/aponeurotic tendon, and angiolymphatics (occipital artery/vein crosses the GON; lymph node presence, within or distal to the trapezial tunnel) (54).

Neuropathy of ON appears to provide safe, durable pain relief in selected patients with chronic headaches caused by ON (Table 2). Factors correlated with a positive outcome include tenderness over the GON, a positive response to GON block or Botox, a history of direct occipital trauma, and preoperatively being under the care of a neurologist or pain specialist (54). Sectioning of the inferior oblique muscle is reported to be effective when occipital pain is exacerbated or triggered by flexion of the cervical spine (52). However, cervicogenic headache is a contraindication of neurolysis (51). Careful preoperative diagnosis is needed.

Occipital nerve stimulation

Recently, successful results with ONS have been reported in the management of intractable headaches (Table 3), including cervicogenic headache, ON, transformed migraine, hemiplegia continua, and cluster headaches. This stimulation technique involves the subcutaneous insertion of electrodes in the C1-C2 region of the posterior cervical spine (Fig. 3). Convergence of afferents from C1-C3 cervical nerves with trigeminal afferents is explained as the cause of the cervicogenic headache that results from activation of these nerves (59). The pain control mechanism of ONS is similar to that of gait control theory, considered in other peripheral nerve stimulation (58). As opposed to destructive surgery, ONS is fully reversible. If the patient does not want to use stimulation, it is easy to stop the stimulation and the device can be removed with a simple procedure.

Other destructive surgeries

The approach to patients with ON must initially be conservative. Although C2 gangliotomies, C2 ganglionectomy, C2 to C3 rhizotomies, C2 to C3 root decompression, and distal neuroectomy have been tried historically for intractable cases, these kinds

Table 3. Summary of noteworthy articles on ONS for ON

| Study            | Study design | No. | Follow-up duration | Outcome measure method | Results | Lead type used |
|------------------|--------------|-----|--------------------|------------------------|---------|----------------|
| Picaza et al. (88) 1977 | Retrospective | 6   | 12-46 mon          | N/A                    | 3/6, good to excellent | N/A            |
| Weiner et al. (64) 1999     | Retrospective | 13  | (1.5-6 yr)         | > 50% pain relief      | 92% positive result | Cylinder type  |
| Oh et al. (66) 2004 (paddle) | Retrospective | 20 (10 ON, 10 migraine) | 1-6 mon               | > 50% pain relief | 1 mon 100% (20/20) 6 mon 94% (17/18) | Paddle type |
| Kapural et al. (87) 2005    | Retrospective | 6   | 3 mon              | VAS                    | VAS 8 → 2 PDI 48 → 14 | Paddle type |
| Rodrigo-Royo et al. (89) 2005 | Retrospective | 4   | 4-16 mon           | 50% pain reduction     | Improved in all    | Cylinder type  |
| Slavin et al. (58) 2006     | Retrospective | 14  | Mean 22 mon (5-32 mon) | VAS 50% reduction | 70% positive     | Cylinder type  |
| Johnstone and Sundaraj (65) 2006 | Retrospective | 7   | Mean 25 mon (6-47 mon) | VAS 50% reduction Opioid doses | 5/7 (71%) positive Reduction in all cases | Paddle type |

ONS, occipital nerve stimulation; ON, occipital neuralgia; No., number; N/A, not available; VAS, visual analog scale; PDI, pain disability index.

Table 4. Summary of noteworthy articles on destructive surgery for ON

| Study            | Study design | Surgical method | No. | Follow-up duration | Outcome measure method | Results           |
|------------------|--------------|-----------------|-----|--------------------|------------------------|-------------------|
| Sharma et al. (90) 2005 | Retrospective | Neulectomy      | 22  | 6 wk 18 mon        | Pain relief            | Relief in 90% Relief in 70% |
| Dubuisson (21) 1995     | Retrospective | Rhizotomy at C1-3 | 14  | 33 mon (3-66)      | > 50% pain reduction  | 71% positive result |
| Wang and Levi (56) 2002 | A case report | Ganglionectomy of C2 | 1   | N/A                | N/A                   | Pain relief (+)   |

ON, occipital neuralgia; No., number; N/A, not available.
of destructive surgeries risk the development of painful neuroma, causalgia, or intractable neuropathic pain, and thus their use is decreasing. The studies conducted with destructive surgeries are listed in Table 4.

**POTENTIAL COMPLICATIONS AND RED FLAGS**

**Complications of interventional management**

Infection or bleeding may result from any percutaneous technique, though these are usually minor problems. A case of sudden unconsciousness due to inadvertent subarachnoid injection in a patient with a craniotomy defect has been reported (60). Temporary dizziness, injection site soreness, focal alopecia, and paresthesia due to nerve injury should be anticipated (61-63).

**Complications of ONS**

Poor outcomes after electrode implantation are a common problem that has been reported following up to 30% of implantations. Therefore, a test stimulation before permanent implantation is recommended in many studies. Permanent implantation is usually recommended when 50% pain reduction occurs on test stimulation.

Lead migration (4%, 2/54) and postsurgical infection (12%, 6/50) are relatively common and well-known complications. Fracture and disconnection of the lead (2%, 1/50) and implant-related allergic reactions (3%, 1/37) can occur, though rarely (58,64-68).

**CONCLUSION**

Occipital neuralgia is defined by the IHS as paroxysmal shooting or stabbing pain in the dermatomes of the GON or LON (1). The GON is the medial branch of the dorsal ramus of the C2 spinal nerve. The GON initially courses in a downward, lateral direction, makes the bend along the inferior oblique and is covered by the splenius capitis, the longissimus, and the semispinalis muscles. The GON then turns upward and pierces the semispinalis capitis. Finally, it turns superolaterally to emerge into the scalp by piercing the aponeurotic fibrous attachment of the trapezius muscle and SCM to the superior nuchal line (11-13). On diagnosis, tumors, infections, vascular problems (e.g., posterior circulation hemorrhage or infarction), and congenital anomalies (e.g., Arnold-Chiari malformation) should be ruled out first. Various treatment methods exist, from medical treatment to open surgical procedures.

Clinicians should always remember that destructive procedures carry grave risks: once an anatomic structure is destroyed, it cannot be easily recovered, if at all, and with any destructive procedure there is always the risk of the development of painful neuroma or causalgia, conditions that may be even harder to control than the original complaint (58). The treatment of ON should be performed through adequate algorithm (Fig. 4).

**ACKNOWLEDGMENT**

The authors thank Dr. Young hee Baek for helpful advice on this article, and Il Hee So, Eui Soo Shin, Yeon Mi Kim, and Eugene Jung of Asan Medical Library for their efforts in data collection.

**DISCLOSURE**

The authors have no potential conflicts of interest to disclose.

**AUTHOR CONTRIBUTION**

Conception and design: Jeon SR, Choi I. Acquisition of data: Choi I. Analysis and interpretation of data: Choi I. Drafting the article: Choi I. Critically revising the article: Jeon SR, Choi I. Reviewed submitted version of manuscript: Jeon SR, Choi I. Statistical analysis: Choi I. Administrative/technical/material support: Jeon SR. Study supervision: Jeon SR. Approval of the final manuscript on behalf of all authors: Jeon SR.

**ORCID**

Il Choi http://orcid.org/0000-0003-0120-6564
REFERENCES

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd ed. *Cephalalgia* 2004; 24 Suppl 1: 9-160.

2. Hammond SR, Danta G. Occipital neuralgia. *Clin Exp Neurol* 1978; 15: 258-70.

3. Koopman JS, Dielemann JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. *Pain* 2009; 147: 122-7.

4. Cohen SP, Plunkett AR, Wilkinson I, Nguyen C, Kurihara C, Flagg A 2nd, Mason JO 3rd, Katz B, Greene HH. Severe ocular pain secondary to ocular myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. *Clin J Sport Med* 2001; 11: 235-8.

5. Magnússon T, Ragnarsson T, Björnsson A. Occipital nerve release in patients with whiplash trauma and occipital neuralgia. *Headache* 1996; 36: 32-6.

6. Mason JO 3rd, Katz B, Greene HH. Severe ocular pain secondary to occipital neuralgia following vitrectomy surgery. *Retina* 2004; 24: 458-9.

7. Kuhn WE, Kuhn SC, Gilberstadt H. Occipital neuralgia: clinical recognition of a complicated headache. A case series and literature review. *J Otofac Pain* 1997; 11: 158-65.

8. Perelson HN. Occipital nerve tenderness: a sign of headache. *South Med J* 1947; 40: 653-6.

9. Vanek P, Latatera A, Levy R, Mekhail N, van Kleeft M, Van Zundert J. Incidence of facial pain in the general population. *Clin Exp Neurol* 2006; 43: 231-9.

10. Tobin J, Flettman S. Occipital nerve blocks: when and what to inject? *Headache* 2009; 49: 1521-33.

11. Bogduk N. The clinical anatomy of the cervical dorsal rami. *Spine* 1982; 7: 319-30.

12. Rifat SF, Lombardo JA. Occipital neuralgia in a football player: a case report. *Clin J Sport Med* 1995; 5: 251-3.

13. Mosser SW, Guyuron B, Janis JE, Rohrich RJ. The anatomy of the greater occipital nerve: implications for the etiology of migraine headaches. *Plast Reconstr Surg* 2004; 113: 693-7.

14. Inan N, Ceyhan A, Inan L, Kavakligolu O, Alptekin A, Unal N. C2/C3 nerve blocks and greater occipital nerve block in cervicogenic headache treatment. *Func Neurol* 2001; 16: 239-43.

15. Dash KS, Janis JE, Guyuron B. The lesser and third occipital nerves and migraine headaches. *Plast Reconstr Surg* 2005; 115: 1752-8.

16. Natsis K, Baraliakos X, Appell HJ, Tsikaras P, Gigis I, Koebeke J. The course of the greater occipital nerve in the suboccipital region: a proposal for setting landmarks for local anesthesia in patients with occipital neuralgia. *Clin Anat* 2006; 19: 332-6.

17. Becsor N, Bovim G, Sjaastad O. Extracranial nerves in the posterior part of the head. Anatomic variations and their possible clinical significance. *Spine* 1998; 23: 1435-41.

18. Tubbs RS, Salter EG, Wellons JC, Blount JP, Oakes WJ. Landmarks for the identification of the cutaneous nerves of the occiput and nuchal regions. *Clin Anat* 2007; 20: 235-8.

19. Hollinshead WH. Anatomy for Surgeons. New York, NY: Harper & Row, 1969.

20. Bogduk N, Marsland A. On the concept of third occipital headache. *J Neurol Neurosurg Psychiatry* 1986; 49: 775-80.

21. Dubuisson D. Treatment of occipital neuralgia by partial rhizotomy at C1-3. *J Neurosurg* 1995; 82: 581-6.

22. Bogduk N. Cervicogenic headache: anatomic basis and pathophysiologic mechanisms. *Curr Pain Headache Rep* 2001; 5: 382-6.

23. Le Doaré K, Akerman S, Holland PR, Lasalandra MP, Bergerot A, Classey JD, Knight YE, Goadsby PJ. Occipital afferent activation of second order neurons in the trigemino-cervical complex in rat. *Neurosci Lett* 2006; 403: 73-7.

24. Pióvesan EJ, Kowacs PA, Tatsui CE, Lange MC, Ribas LC, Werneck LC. Referred pain after painful stimulation of the greater occipital nerve in humans: evidence of convergence of cervical afferences on trigeminal nuclei. *Cephalalgia* 2001; 21: 107-9.

25. Vital JM, Grenier E, Dautheribes M, Baspeyre H, Lavignolle B, Sénéugas J. An anatomic and dynamic study of the greater occipital nerve (n. of Arnold). Applications to the treatment of Arnold’s neuralgia. *Surg Radiol Anat* 1989; 11: 205-10.

26. Ashkenazi A, Levin M. Three common neuralgias. How to manage trigeminal, occipital, and postheraptic pain. *Postgrad Med* 2004; 116: 16-8.

27. Loukas M, El-Sedy A, Tubbs RS, Louis RG Jr, Wartmann CH, Curry B, Jordan R. Identification of greater occipital nerve landmarks for the treatment of occipital neuralgia. *Folia Morphol (Warsz)* 2006; 65: 337-42.

28. Handel T, Kaplan R. Occipital neuralgia. In: Frontera WR, Silver JK, editors. Essentials of Physical Medicine and Rehabilitation. Philadelphia, PA: Hanley and Bellfus, 2002.

29. Beruto LJ, Ramos MM. Decades de med y cirug pract. *Madrid* 1821; 3: 145-69.

30. Trescot AM. Headache management in an interventionl pain practice. *Pain Physician* 2000; 3: 197-200.

31. Martelletti P. Proinflammatory pathways in cervicogenic headache. *Clin Exp Rheumatol* 2000; 18: S33-8.

32. Martelletti P, van Suijlekom H. Cervicogenic headache: practical approaches to therapy. *CNS Drugs* 2004; 18: 793-805.

33. Anthony M. Headache and the greater occipital nerve. *Clin Neurol Neurosurg* 1992; 94: 297-301.

34. Tsui JK, Eisen A, Stoesel AJ, Calne D, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. *Lancet* 1986; 2: 245-7.

35. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. *Otolaryngol Head Neck Surg* 2000; 123: 669-76.

36. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. *Toxicol* 2000; 38: 245-58.

37. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. *Headache* 2004; 44: 35-42.

38. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. *Pain Pract* 2010; 10: 137-44.

39. Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, Choi I, et al. Headache and the greater occipital nerve. *Clin Neurol Neurol* 2007; 20: 235-8.
aches associated with pericranial muscle tension. *Headache* 1998; 38: 468-71.

41. Zlotnik G. Re: "Botulinum toxin type A as a migraine preventive treatment" (Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group. *Headache*. 2000;40:445-450). *Headache* 2001; 41: 606-7.

42. Taylor M, Silva S, Cottrell C. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. *Headache* 2008; 48: 1476-81.

43. Kapural L, Stillman M, Kapural M, McIntyre P, Guirgis M, Mekhail N. Botulinum toxin occipital nerve block for the treatment of severe occipi-
tal neuralgia: a case series. *Pain Pract* 2007; 7: 337-40.

44. Chua NH, Vissers KC, Sluijter ME. Pulsed radiofrequency treatment in interventional pain management: mechanisms and potential indications-a review. *Acta Neurochir (Wien)* 2011; 153: 763-71.

45. Hagivara S, Iwasaka H, Takeshima N, Noguchi T. Mechanisms of analgesic action of pulsed radiofrequency on adjuvant-induced pain in the rat: roles of descending adrenergic and serotonergic systems. *Eur J Pain* 2009; 13: 249-52.

46. Navani A, Mahajan G, Kreis P, Fishman SM. A case of pulsed radiofrequency lesioning for occipital neuralgia. *Pain Med* 2006; 7: 453-6.

47. Choi HJ, Oh IH, Choi SK, Lim YJ. Clinical outcomes of pulsed radiofrequency neuromodulation for the treatment of occipital neuralgia. *J Korean Neurosurg Soc* 2012; 51: 281-5.

48. Huang JH, Galvagno SM Jr, Hameed N, Wilkinson I, Erdik MA, Patel A, Buckenmaier C 3rd, Rosenberg J, Cohen SP. Occipital nerve pulsed radiofrequency treatment: a multi-center study evaluating predictors of outcome. *Pain Med* 2012; 13: 489-97.

49. Vanelderen P, Rouwette T, De Vooght P, Puyhaert M, Heylen R, Vissers K, Van Zundert J. Pulsed radiofrequency for the treatment of occipital neuralgia: a prospective study with 6 months of follow-up. *Reg Anesth Pain Med* 2010; 35: 148-51.

50. Poletti CE. Proposed operation for occipital neuralgia: C-2 and C-3 root decompression. Case report. *Neurosurgery* 1983; 12: 221-4.

51. Bovim G, Fredriksen TA, Stolt-Nielsen A, Sjaastad O. Neurolysis of the greater occipital nerve in cervicogenic headache. A follow up study. *Headache* 1992; 32: 175-9.

52. Gille O, Lavigneolle B, Vital JM. Surgical treatment of greater occipital neuralgia by neurolysis of the greater occipital nerve and sectioning of the inferior oblique muscle. *Spine* 2004; 29: 828-32.

53. Gayuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. *Plast Reconstr Surg* 2005; 115: 1-9.

54. Ducic I, Hartmann EC, Larson EE. Indications and outcomes for surgical treatment of patients with chronic migraine headaches caused by occipi-
tal neuralgia. *Plast Reconstr Surg* 2009; 123: 1453-61.

55. Stechison MT, Mullin BB. Surgical treatment of greater occipital neural-
ga: an appraisal of strategies. *Acta Neurochir (Wien)* 1994; 131: 236-40.

56. Wang MY, Levi AD. Ganglionectomy of C-2 for the treatment of medically refractory occipital neuralgia. *Neurosurg Focus* 2002; 12: E14.

57. Kapoor V, Rothfus WE, Grahovac SZ, Amin Kassam SZ, Horowitz MB. Refractory occipital neuralgia: preoperative assessment with CT-guided nerve block prior to dorsal cervical rhizotomy. *AJNR Am J Neuroradiol* 2003; 24: 2105-10.

58. Slavin KV, Nersesyan H, Wess C. Peripheral neurostimulation for treatment of intractable occipital neuralgia. *Neurosurgery* 2006; 58: 112-9.

59. Goadsby PJ, Knight YE, Hoskin KL. Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat. *Pain* 1997; 73: 23-8.

60. Okuda Y, Matsumoto T, Shinohora M, Kitajima T, Kim P. Sudden unconsciousness during a lesser occipital nerve block in a patient with the occipital bone defect. *Eur J Anaesthesiol* 2001; 18: 829-32.

61. Leinsch-Dahlke E, Jürgens T, Bogdahn U, Jakob W, May A. Greater occipital nerve block is ineffective in chronic tension type headache. *Cephalalgia* 2005; 25: 704-8.

62. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes—prolonged effects from a single in-
jection. *Pain* 2006; 122: 126-9.

63. Naja ZM, El-Rajab M, Al-Tannir MA, Ziade FM, Tawfik OM. Repetitive occipital nerve blockade for cervicogenic headache: expanded case report of 47 adults. *Pain Pract* 2006; 6: 278-84.

64. Weiner RL, Reed KL. Peripheral neurostimulation for control of intracta-
ble occipital neuralgia. *Neuromodulation* 1999; 2: 217-21.

65. Johnstone CS, Sundaraj R. Occipital nerve stimulation for the treatment of occipital neuralgia-eight case studies. *Neuromodulation* 2006; 9: 41-7.

66. Oh MY, Ortega J, Bellotte JB, Whiting DM, Alo K. Peripheral nerve stimula-
tion for the treatment of occipital neuralgia and transformed migraine using a c1-2-3 subcutaneous paddle style electrode: a technical report. *Neuromodulation* 2004; 7: 103-12.

67. Kapural L, Mekhail N, Hayek SM, Stanton-Hicks M, Malak O. Occipital nerve electrical stimulation via the midline approach and subcutaneous surgical leads for treatment of severe occipital neuralgia: a pilot study. *Anesth Analg* 2005; 101: 171-4.

68. Jasper JF, Hayek SM. Implanted occipital nerve stimulators. *Pain Physi-
cian* 2008; 11: 187-200.

69. White JB, Atkinson PP, Cloft HJ, Atkinson JL. Vascular compression as a potential cause of occipital neuralgia: a case report. *Cephalalgia* 2008; 28: 78-82.

70. Hashiguchi A, Mimata C, Ichimura H, Kuratsu J. Occipital neuralgia as a presenting symptom of cervicomedullary dural arteriovenous fistula. *Headache* 2007; 47: 1095-7.

71. Bruni G, Mostardini C, Pierallini A, Villani V, Modini C, Cerbo R. Neurovascular headache and occipital neuralgia secondary to bleeding of bul-
bocervical cavernoma. *Cephalalgia* 2007; 27: 1074-9.

72. Cerrato P, Bergui M, Imperiale D, Baima C, Giraudo M, Lentini A, Lopiano L, Bradac GB, Bergamasco B. Occipital neuralgia as isolated symptom of an upper cervical cavernous angioma. *J Neurol* 2002; 249: 1464-5.

73. Pfadenhauer K, Weber H. Giant cell arteritis of the occipital arteries—a prospective color coded duplex sonography study in 78 patients. *J Neurol* 2003; 250: 844-9.

74. González-Gay MA, García-Porrúa C, Brañas F, Alba-Losada J. Giant cell arteritis presenting as occipital neuralgia. *Clin Exp Rheumatol* 2001; 19: 479.

75. Jundt JW, Mock D. Temporal arteritis with normal erythrocyte sedimentation rates presenting as occipital neuralgia. *Arthritis Rheum* 1991; 34: 217-9.

76. Kim K, Mizunari T, Kobayashi S, Ishii S, Teramoto A. Occipital neuralgia caused by the compression of the fenesstrated vertebral artery: a case re-
port. *No Shinkei Geka* 1999; 27: 645-50.

77. Sharma RR, Parekh HC, Prabhu S, Gurusinghe NT, Bertolus G. Compression of the C-2 root by a rare anomalous ectatic vertebral artery. Case re-

 strikeouts.
port. J Neurosurg 1993; 78: 669-72.
78. Garza I. Cranio-cervical junction schwannoma mimicking occipital neuralgia. Headache 2007; 47: 1204-5.
79. Ballesteros-Del Rio B, Ares-Luque A, Tejada-Garcia J, Muela-Molinero A. Occipital (Arnold) neuralgia secondary to greater occipital nerve schwannoma. Headache 2003; 43: 804-7.
80. Boes CJ. C2 myelitis presenting with neuralgiform occipital pain. Neurology 2005; 64: 1093-4.
81. De Santi L, Monti L, Menci E, Bellini M, Annunziata P. Clinical-radiologic heterogeneity of occipital neuralgiform pain as multiple sclerosis relapse. Headache 2009; 49: 304-7.
82. Tancredi A, Caputi F. Greater occipital neuralgia and arthrosis of C1-2 lateral joint. Eur J Neurol 2004; 11: 573-4.
83. Postacchini F, Giannicola G, Cinotti G. Recovery of motor deficits after microdiscectomy for lumbar disc herniation. J Bone Joint Surg Br 2002; 84: 1040-5.
84. Baer-Henney S, Tatagiba M, Samii M. Osteochondroma of the cervical spine causing occipital nerve neuralgia. Case report. Neurol Res 2001; 23: 777-9.
85. Piovesan EJ, Werneck LC, Kovacs PA, Tatsui C, Lange MC, Carraro Júnior H, Wittig EO. Greater occipital neuralgia associated with occipital osteolytic lesion. Case report. Arq Neuropsiquiatr 1999; 57: 114-9.
86. Clavel M, Clavel P. Occipital neuralgia secondary to exuberant callus formation. Case report. J Neurosurg 1996; 85: 1170-1.
87. Volcy M, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia 2006; 26: 336-40.
88. Picaza JA, Hunter SE, Cannon BW. Pain suppression by peripheral nerve stimulation. Chronic effects of implanted devices. Appl Neurophysiol 1977-1978; 40: 223-34.
89. Rodrigo-Royo MD, Azcona JM, Quero I, Lorente MC, Acín P, Azcona J. Peripheral neurostimulation in the management of cervicogenic headache: four case reports. Neuromodulation 2005; 8: 241-8.
90. Sharma RR, Devadas RV, Pawar SJ, Lad SD, Mahapatra AK. Current status of peripheral neurectomy for occipital neuralgia. Neurosurg Q 2005; 15: 232-8.
91. Tubbs RS, Mortazavi MM, Loukas M, D‘Antoni AV, Shoja MM, Cohen-Gadol AA. Cruveilhier plexus: an anatomical study and a potential cause of failed treatments for occipital neuralgia and muscular and facet denervation procedures. J Neurosurg 2011; 115: 929-33.